MegaLab combines biological capabilities with automation and artificial intelligence, and is committed to improving R&D capabilities in the frontier fields of life sciences. MegaLab has independently developed a variety of high-throughput and high-efficiency automation platforms for biological experiments. At present, MegaLab has built a number of automation platforms for different biological scenarios, including MegaCell automatic cell experiment platform, MegaMolecule automatic molecular experiment platform, MegaMicro ultra-high throughput automatic virus nucleic acid detection system, and MegaOmics omics sample pretreatment intelligent automation platform.
The intelligent automated biological platform applied by MegaLab uses robots as the medium, relies on highly intelligent scheduling engines, and shields the differences between various devices through a set of concise and clear graphical interface software, thereby integrating various automation equipment required for the experimental process. At the same time, MegaLab is equipped with IntellVega, an AI vision platform which integrates robotics, 2D and 3D machine vision, and deep learning, and was developed MegaRobo.
Currently, MegaLab has brought together a high-caliber interdisciplinary team of biologists, pharmacists, bioinformaticians, data scientists and engineers. Through the deep integration of robotics, automation, artificial intelligence and biological capabilities, they continuously explore the application of intelligent automation in multiple biological vertical fields such as drug research and development, genetic engineering, clinical diagnosis, synthetic biology, regenerative medicine, and immunology.

Professor Zheng Lemin, Deputy Director of the Peking University Institute of Cardiovascular Sciences, and assistant director of a key laboratory designated by the Ministry of Education. He serves as the director of the Cardiometabolism and Proteomics Laboratory, researcher (tier-3 professor), and doctoral advisor in pathophysiology. Prof. Zheng earned an undergraduate degree in chemistry at Beijing Normal University, and then worked in the Institute of Photosensitive Chemistry, Chinese Academy of Sciences. In 2000, he entered Cleveland Clinic, the No. 1 hospital for cardiology and heart surgery in the United States, to study for his doctorate in clinical bioanalytical chemistry.After obtaining his doctorate, Prof. Zheng worked for a biomedical company affiliated with Cleveland Clinic. In 2007, he joined the Peking University Institute of Cardiovascular Sciences as an associate professor and lab director. In 2014, Prof. Zheng began to serve as a doctoral advisor; in 2015, he began to serve as a researcher, doctoral advisor and research director at the School of Basic Medicine, Peking University. In 2018, he served as Deputy Director of the Peking University Institute of Cardiovascular Sciences and assistant director of a key laboratory designated by the Ministry of Education. Currently, he is a member of the basic medicine group of the Chinese Society of Cardiology, deputy secretary general of the Precision Medicine Branch Of Chinese Society of Cardiothoracic and Vascular Anesthesiology, head of the Lipid Metabolism Group of the Vascular Branch of the Beijing Physiological Association, and a member of the Chinese Association of Pathophysiology. He used to serve as Vice Director of the Cardiovascular Evidence-Based and Precision Medicine Committee of the Chinese Research Hospital Association, and Deputy Director of the Chinese Society of Lipids and Lipoproteins.